

Embargoed until 21 Jun 2024

INTENDED FOR USE WITH MEDICAL AND NON-MEDICAL MEDIA IN THE UK ONLY

NICE ENABLES ACCESS TO FIRST TREATMENT THAT TARGETS THE UNDERLYING PATHOPHYSIOLOGY OF RARE DISEASE X-LINKED HYPOPHOSPHATAEMIA (XLH) IN ADULTS¹

Kyowa Kirin is delighted by the decision made today by the National Institute for Health and Care Excellence (NICE) to recommend CRYSVITA[®] for the treatment of adults living with X-linked hypophosphataemia (XLH) in England, Wales and Northern Ireland

London, England. 21 June 2024 – Adults living with the rare disease X-linked hypophosphataemia (XLH) in England, Wales and Northern Ireland will now have access to the first available treatment to tackle the underlying cause of XLH following NICE's decision to recommend burosumab (marketed as Crysvida) to treat adults who have a confirmed diagnosis of XLH, following a new access deal.¹

This decision ensures equal access to burosumab across the UK, as adults living with XLH in Scotland have been able to access burosumab on the NHS since March 2023, following approval by the Scottish Medicines Consortium (SMC) through their ultra-orphan pathway.² Burosumab is also available for eligible children and adolescents in all four UK nations.

Initially, NICE published an interim negative decision in its Appraisal Consultation Document (ACD). Following constructive engagement between Kyowa Kirin, NICE and NHS England, this recommendation was revised and an agreement for long term commissioning reached, thus resulting in a positive decision in its Final Draft Guidance (FDG).

XLH is a very rare genetic condition, affecting roughly 1.7 – 4.8 per 100,000 people.³ This rare metabolic bone condition is a life-long and progressive disease that typically presents in early childhood, causing bowed legs, stunted growth, and bone and joint pain.⁴ It is a whole life, whole body, and whole family disease, according to people living with the condition, as several family members are often impacted due to its inherited nature.⁵ XLH also has an adverse impact on emotional wellbeing for various reasons including pain, uncertainty about the future, and may also be associated with financial challenges.^{5,6} XLH does not just affect individuals with the disease, but also their family and friends, who are often involved in their support and care.⁶

Responding to NICE's final recommendation:

Oliver Gardiner, Trustee and Co-Founder of XLH UK, said: "This is fantastic news for adults living with XLH in England and Wales, for whom treatment options are currently severely limited and who, as a result of this recommendation, will have access to an effective treatment".

Embargoed until 21 Jun 2024

INTENDED FOR USE WITH MEDICAL AND NON-MEDICAL MEDIA IN THE UK ONLY

Dr Gavin Clunie, Consultant Rheumatologist and Metabolic Bone Physician at Addenbrooke's Hospital, said: "It is welcome that NICE have decided to recommend burosumab for the treatment of adults living with XLH, given the clinical benefit to these patients and significant unmet need. This is a milestone development for those adults living with XLH who need this treatment."

Emma Claeys, General Manager UK, Kyowa Kirin, said: "We are pleased that, following positive engagement with NICE and feedback from the patient and clinical community, this positive outcome demonstrates Kyowa Kirin's commitment to delivering access to innovative treatments to people living with rare diseases in the United Kingdom."

Burosumab is currently the only licensed medicine that addresses the underlying causes (pathophysiology) of XLH, rather than only the symptoms. The drug is now reimbursed in several European countries for both the paediatric and adult populations, including France, Germany, Italy and Spain.^{7,8,9}

//

Notes to editor:

About X-linked hypophosphataemia

XLH is caused by a genetic mutation which leads to overexpression of the protein FGF23, a protein involved in the regulation of phosphate concentration in the blood. In XLH, FGF23 is produced in excess leading to depletion of phosphate in the blood, known as hypophosphataemia.¹⁰

Individuals living with the disease may display a multitude of symptoms including short stature, limb deformities, bone and joint pain, oral abscesses, and hearing loss.¹¹ To manage this wide variety of symptoms, the disease is managed through multi-disciplinary teams.¹²

About CRYSVITA® (burosumab) in XLH

Burosumab is a recombinant human monoclonal antibody that binds to the protein FGF23. This has the impact of inhibiting the action of FGF23, allowing phosphate regulation in the body to be restored.¹²

In 2018, the European Commission granted a conditional marketing authorisation for burosumab for the treatment of XLH with radiographic evidence of bone disease in children one year of age and older and in adolescents with growing skeletons.¹³ Following this, the European Commission granted burosumab a conditional marketing authorisation in 2020, for the treatment of adolescents regardless of growth status and adults with XLH.¹⁴ The licence was then converted from a conditional to a full standard marketing authorisation in 2022,¹⁵ and has been approved by the MHRA via the reliance route.¹⁶ The drug is now reimbursed in several European countries for both the paediatric and adult population, including France, Germany and Italy.^{7,8,9}

Embargoed until 21 Jun 2024**INTENDED FOR USE WITH MEDICAL AND NON-MEDICAL MEDIA IN THE UK ONLY**

About Kyowa Kirin

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan based global specialty pharmaceutical company with a heritage of more than 70 years, the company applies cutting-edge science, including expertise in antibody research and engineering, to address the needs of patients across multiple therapeutic areas such as nephrology, oncology, immunology/allergy and neurology. Across its four regions – Japan, Asia Pacific, North America and EMEA/International – Kyowa Kirin focuses on its purpose, to make people smile, and is united by its shared values of commitment to life, teamwork, innovation and integrity.

You can learn more about Kyowa Kirin International at: <https://international.kyowa-kirin.com>

Contacts for Kyowa Kirin

Media

Stacey Minton: stacey.minton@kyowakirin.com

Victoria Hayes: victoria.hayes@kyowakirin.com

References

-
- ¹ National Institute for Health and Care Excellence. Burosumab for treating X-linked hypophosphataemia in adults [ID3822]. [Available here](#). [Last accessed May 2024].
 - ² Kyowa Kirin. Scottish Medicines Consortium (SMC) Enables Access to First Treatment Tackling the Underlying Cause of X-Linked Hypophosphataemia (XLH) in Adults. 2023. [Available here](#). [Last accessed May 2024].
 - ³ Giannini S. et al. Burden of disease and clinical targets in adult patients with X-linked hypophosphatemia. A comprehensive review. *Osteoporos Int*. 2021. [Available here](#). [Last accessed May 2024].
 - ⁴ Skrinar A, et al. The lifelong impact of X-linked hypophosphatemia: Results from a burden of disease survey. *J Endocr Soc*. 2019. [Available here](#). [Last accessed May 2024].
 - ⁵ Hamilton AA, et al. Whole Body, Whole Life, Whole Family: Patients' Perspectives on X-Linked Hypophosphatemia. *J Endocr Soc*. 2022 [Available here](#). [Last accessed May 2024].
 - ⁶ Lo SH, et al. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study. *Qual Life Res*. 2020. [Available here](#). [Last accessed May 2024].
 - ⁷ Haute Autorité de Santé. Transparency Committee Summary. 2021. [Available here](#). [Last accessed May 2024].
 - ⁸ Gemeinsamer Bundesausschuss. Justification of the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section

Embargoed until 21 Jun 2024

INTENDED FOR USE WITH MEDICAL AND NON-MEDICAL MEDIA IN THE UK ONLY

35a SGB V Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years). 2021. [Available here](#). [Last accessed May 2024].

⁹ Agenzia Italiana del Farmaco. Determina Crysvida, 2023. [Available here](#). [Last accessed May 2024].

¹⁰ Beck-Nielsen S.S. et al. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet J Rare Dis. 2019. [Available here](#). [Last accessed May 2024].

¹¹ Kubota T. X-Linked Hypophosphatemia Transition and Team Management. Endocrines. 2022. [Available here](#). [Last accessed May 2024].

¹² Electronic Medicines Compendium. Crysvida 10 mg solution for injection. [Available here](#). [Last accessed May 2024].

¹³ European Medicines Agency. CRYSVITA EPAR product information. Summary of Product Characteristics. [Available here](#). [Last accessed: May 2024].

¹⁴ Kyowa Kirin. Kyowa Kirin Announces European Commission (EC) Approval of CRYSVITA® (burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults. 2020. [Available here](#). [Last accessed May 2024].

¹⁵ European Medicines Agency. Crysvida. EPAR. 2023. [Available here](#). [Last accessed May 2024].

¹⁶ Scottish Medicines Consortium, 2023. Burosumab solution for injection (Crysvida®). [Available here](#). [Last accessed May 2024].